RMD · Full Picture

RESMED INC — the full picture

Trailing window · 2026-05-12 to 2026-08-10

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

1. Capital Return Program · Buybacks & dividendsPriority 78
   -14.4% cash (realized); 2 sources (news, press_release); 3 forward row(s); quote_verified
   Guiding to more than $1.85 billion in capital to be returned to shareholders through share repurchases and dividends during FY 2027
2. Revenue Performance and Mix · Revenue growth & mixPriority 75
   +1.0% revenue; 2 sources (news, press_release); 2 forward row(s); quote_verified
   Analysts project ResMed 2027 revenues of US$5.80 billion.
3. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 69
   2 sources (news, press_release); 6 forward row(s); quote_verified
   Announced agreement to sell MatrixCare business; transaction expected to close during the first quarter of Resmed’s fiscal year 2027
4. Guidance / Outlook · Guidance & outlookPriority 59
   +3.0% revenue; 2 forward row(s); quote_verified
   Guidance for FY2027 core revenue growth was stated as 5%-7% and non-GAAP EPS guidance of $12 to $12.25.
5. Operating Margin Drivers · Operating income & profitabilityPriority 55
   +8.4% net_income (realized); quote_verified
   Net income for twelve months ended June 30, 2026: $1,523,293 thousand vs $1,400,723 thousand prior year
6. Operating Cash Flow Trends · Cash flow generationPriority 54
   2 sources (news, press_release); quote_verified
   ResMed generated $1.6 billion in free cash flow for the full fiscal year.
7. Income Tax Rate Changes · TaxPriority 53
   quote_verified
   FY 2026 income taxes: $396,123 thousand; FY 2025 income taxes: $276,843 thousand
8. Geographic Market Commentary · Geographic mixPriority 50
   quote_verified
   Americas Sleep and Breathing Health revenue grew 8% in the fourth quarter
9. Astral Ventilator Sales Suspension · UnclassifiedPriority 49
   1 forward row(s); quote_verified
   ResMed's FY2027 guidance assumes no Astral ventilator sales in fiscal 2027, reducing expected revenue by an estimated $75 million.
10. Astral FDA Recall · Regulatory action & investigationsPriority 48
    quote_verified
    ResMed suspended new sales of its Astral ventilator following an FDA recall/field safety action.
11. Market Demand Trends · Demand, orders & backlogPriority 47
    2 sources (news, press_release); quote_verified
    Demand for sleep devices and masks increased.
12. Gross Margin Drivers · Gross marginPriority 44
    2 sources (news, press_release); quote_verified
    Three months ended June 30, 2026 cost of sales: $602,431 thousand; gross profit $861,216 thousand

Threads by pillar

Revenue & Demand Priority 80 · 4 threads

• Revenue Performance and MixPriority 75 · News, Release
• Geographic Market CommentaryPriority 50 · Release
• Market Demand TrendsPriority 47 · News, Release
• Product Launch and TransitionPriority 35 · Release

Costs & Margins Priority 64 · 5 threads

• Operating Margin DriversPriority 55 · Release
• Net Income and EPS PerformancePriority 34 · News
• Gross Margin DriversPriority 44 · News, Release
• Operating Expense TrendsPriority 37 · Release
• Supply Chain ConstraintsPriority 21 · News

Capital & Balance Sheet Priority 84 · 5 threads

• Capital Return ProgramPriority 78 · News, Release
• Quarterly Dividend DeclarationPriority 37 · Release
• Operating Cash Flow TrendsPriority 54 · News, Release
• Income Tax Rate ChangesPriority 53 · Release
• Liquidity and Debt PositionPriority 42 · Release

Strategy & Portfolio Priority 70 · 2 threads

• Acquisition / Partnership / DivestiturePriority 69 · News, Release
• Strategic Digital Health ExpansionPriority 24 · Release

Legal, Regulatory & Policy Priority 48 · 1 thread

• Astral FDA RecallPriority 48 · News

Guidance & Outlook Priority 59 · 1 thread

• Guidance / OutlookPriority 59 · News

Macro & Market Conditions Priority 35 · 3 threads

• FX / Currency ImpactPriority 31 · Release
• Sleep Apnea Treatment CompetitionPriority 26 · News
• Macroeconomic Factors ImpactPriority 21 · News

Unclassified Priority 51 · 2 threads

• Astral Ventilator Sales SuspensionPriority 49 · News
• Home-Based Therapy AdoptionPriority 23 · News

Expected impact by metric